Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple exercise program may shield breast cancer patients from nerve damage

NCT ID NCT04583124

Symptom relief Sponsor: Universidad de Granada Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a program of therapeutic exercise and relaxation techniques (called ATENTO) could prevent nerve damage (neurotoxicity) in women newly diagnosed with breast cancer. 42 women were split into two groups: one started the program before cancer treatment, the other during treatment. Researchers measured quality of life and cognitive function to see which timing worked best.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
therapeutic exercise and vagal activation techniques
What this could lead to
If it works, this could point toward a simple, drug-free way to prevent nerve damage from cancer treatment, improving quality of life for breast cancer patients.
What could go wrong
This is a very small, early study with only 42 participants, so results may not apply to everyone. The intervention is not a treatment for cancer itself, only for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Sep 2021

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * To have 18 years or older * To have a breast cancer diagnosis (Stage I-III) * To be on waiting list for medical adjuvant treatment with risk of central and/or peripheral neurotoxicity. * To have signed the informed consent. * To have medical clearance for participation. Exclusion Criteria: * To have a previous history of cancer or any cancer treatment. * Pregnant patients. * To participate in another intervention that could influence on the outcomes. * To have a neurodegenerative disease that affects central or peripheral nervous system and could influence the results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm toxic encephalopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasm

Contacts and locations

Locations

  • University of Granada

    Granada, 18016, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.